Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals Acquisition Helps Millipore's Q4 Sales Grow 50 Percent

NEW YORK (GenomeWeb News) — Millipore yesterday said fourth-quarter revenues increased 50 percent as R&D spending rose 41 percent and profit leapt 1,700 percent.
Total receipts for the three months ended Dec. 31, 2006 increased to $383 million from $256 million year over year.
Compared with the fourth quarter of 2005, sales in the company’s Bioprocess segment was up 42 percent to $224 million, while its Bioscience segment gained 61 percent with sales of $158 million.
In a statement, CEO Martin Madaus attributed much of the growth to improved execution, BioProcess and Bioscience sales and acquisitions, including the purchase in July of Serologicals for $1.4 billion.
R&D spending increased to $23.9 million from $17 million year over year.
The company said profits increased to $18.5 million from $1 million in the year-ago period.
Millipore said it had around $77.5 million in cash and cash equivalents as of Dec. 31.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.